TNF and pancreatic neoplasm: Dextran-conjugated triptolide and triptolide nano-MOFs enhance TNF-α levels, promoting an immune response that ultimately inhibits tumor progression in pancreatic cancer with KRAS mutation, while also reducing toxicity compared to free triptolide [976, 977].